These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23913625)

  • 1. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States.
    Pinheiro SP; Kang EM; Kim CY; Governale LA; Zhou EH; Hammad TA
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1251-7. PubMed ID: 23913625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system.
    Shin J; Cheetham TC; Wong L; Niu F; Kass E; Yoshinaga MA; Sorel M; McCombs JS; Sidney S
    J Am Acad Dermatol; 2011 Dec; 65(6):1117-25. PubMed ID: 21565419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are Food and Drug Administration prescription drug safety plans working? A case study of isotretinoin.
    Fain K; Alexander GC
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1258-62. PubMed ID: 24115318
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply letter: are FDA prescription drug safety plans working? A case study of isotretinoin.
    Fain K; Alexander GC
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):440-1. PubMed ID: 24706420
    [No Abstract]   [Full Text] [Related]  

  • 5. Women's experiences with isotretinoin risk reduction counseling.
    Werner CA; Papic MJ; Ferris LK; Lee JK; Borrero S; Prevost N; Schwarz EB
    JAMA Dermatol; 2014 Apr; 150(4):366-71. PubMed ID: 24258663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comments on: are Food and Drug Administration prescription drug safety plans working? A case study of isotretinoin.
    Van Bennekom CM; Mitchell AA
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):439. PubMed ID: 24706419
    [No Abstract]   [Full Text] [Related]  

  • 7. Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data.
    Teichert M; Visser LE; Dufour M; Rodenburg E; Straus SM; De Smet PA; Stricker BH
    Drug Saf; 2010 Apr; 33(4):315-26. PubMed ID: 20297863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplifying contraception requirements for iPLEDGE: A decision analysis.
    Barbieri JS; Roe AH; Mostaghimi A
    J Am Acad Dermatol; 2020 Jul; 83(1):104-108. PubMed ID: 32068040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoting safe use of isotretinoin by increasing contraceptive knowledge.
    Werner CA; Papic MJ; Ferris LK; Schwarz EB
    JAMA Dermatol; 2015 Apr; 151(4):389-93. PubMed ID: 25650743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. We Pledge to Change iPLEDGE.
    Pierson JC; Ferris LK; Schwarz EB
    JAMA Dermatol; 2015 Jul; 151(7):701-2. PubMed ID: 25853235
    [No Abstract]   [Full Text] [Related]  

  • 11. Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non-users: a drug utilisation study.
    Crijns HJ; van Rein N; Gispen-de Wied CC; Straus SM; de Jong-van den Berg LT
    Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1060-6. PubMed ID: 22228673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isotretinoin and iPledge: a view of results.
    Maloney ME; Stone SP
    J Am Acad Dermatol; 2011 Aug; 65(2):418-419. PubMed ID: 21763564
    [No Abstract]   [Full Text] [Related]  

  • 13. Compliance with pregnancy prevention measures during isotretinoin therapy.
    Collins MK; Moreau JF; Opel D; Swan J; Prevost N; Hastings M; Bimla Schwarz E; Korb Ferris L
    J Am Acad Dermatol; 2014 Jan; 70(1):55-9. PubMed ID: 24157382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era.
    Charrow A; Xia FD; Lu J; Waul M; Joyce C; Mostaghimi A
    PLoS One; 2019; 14(3):e0210445. PubMed ID: 30913210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pox on your practice. iPLEDGE program scars dermatologists.
    Ortolon K
    Tex Med; 2006 May; 102(5):29-31. PubMed ID: 17115578
    [No Abstract]   [Full Text] [Related]  

  • 16. The need for restricted prescription of retinoic acid derivative isotretinoin to prevent retinoid teratogenicity.
    De Santis M; Straface G; Cavaliere A; Nobili E; Caruso A
    Prev Med; 2007; 45(2-3):243-4. PubMed ID: 17640721
    [No Abstract]   [Full Text] [Related]  

  • 17. Contraceptive counseling for iPLEDGE and its burden on dermatologists.
    Owens KE; Jiang SW; Nicholas MW
    Arch Dermatol Res; 2024 May; 316(6):287. PubMed ID: 38805059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in isotretinoin prescribing before and after implementation of the System to Manage Accutane Related Teratogenicity (SMART) risk management program.
    Mendelsohn AB; Governale L; Trontell A; Seligman P
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):615-8. PubMed ID: 15892175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survey of pregnant women using isotretinoin.
    Robertson J; Polifka JE; Avner M; Chambers C; Delevan G; Koren G; Lavigne SV; Martinez LP; Miller RK; Carey JC
    Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):881-7. PubMed ID: 16228976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel patient support program to address isotretinoin adherence: proof-of-concept analysis.
    Eichenfield LF; Krakowski AC
    J Drugs Dermatol; 2015 Apr; 14(4):375-9. PubMed ID: 25844611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.